Equities

Kaken Pharmaceutical Co Ltd

Kaken Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)4,461.00
  • Today's Change23.00 / 0.52%
  • Shares traded209.00k
  • 1 Year change+35.22%
  • Beta0.4276
Data delayed at least 20 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments65,32474,26074,624
Total Receivables, Net23,74419,26820,260
Total Inventory17,16715,56314,980
Prepaid expenses------
Other current assets, total739812749
Total current assets106,974109,903110,613
Property, plant & equipment, net25,35525,49825,734
Goodwill, net------
Intangibles, net7,4626,7418,236
Long term investments20,53217,51117,093
Note receivable - long term------
Other long term assets6171,790590
Total assets171,623166,328165,181
LIABILITIES
Accounts payable7,0996,2195,939
Accrued expenses1,6391,5611,394
Notes payable/short-term debt3,8503,8503,850
Current portion long-term debt/capital leases00--
Other current liabilities, total6,4369,2087,866
Total current liabilities19,02420,83819,049
Total long term debt000
Total debt3,8503,8503,850
Deferred income tax1,9471,7712,229
Minority interest--578578
Other liabilities, total6,8976,8835,578
Total liabilities27,86830,07027,434
SHAREHOLDERS EQUITY
Common stock23,85323,85323,853
Additional paid-in capital11,46211,40611,406
Retained earnings (accumulated deficit)128,506126,135126,347
Treasury stock - common(28613)(30026)(28714)
Unrealized gain (loss)7,1844,7244,551
Other equity, total1,363166304
Total equity143,755136,258137,747
Total liabilities & shareholders' equity171,623166,328165,181
Total common shares outstanding383738
Treasury shares - common primary issue8.078.478.12
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.